Beyond UBE3A: New Conversations About Genotype, Variants, and Future Treatments
At INSYNC-AS 2026, researchers came together to examine how genes beyond UBE3A and differences within UBE3A itself may shape Angelman syndrome and future therapeutic development. Why can Angelman syndrome (AS) look different from one person to another, even when the diagnosis is the same? And could understanding those differences help researchers develop better treatment approaches […]
Foundation for Angelman Syndrome Therapeutics Announces Agreement with Apertura Gene Therapy for Access to Blood-Brain Barrier-Crossing Capsid
Read the press release
Nobel Laureate Frances Arnold Brings Directed Evolution to Angelman Syndrome Research
Nobel laureate Dr. Frances Arnold receives FAST funding to engineer new molecular tools for durable RNA-targeted therapies, bringing world-class expertise to Angelman syndrome research.
FAST at ASGCT 2026
FAST leadership takes the stage at ASGCT’s Annual Meeting, driving key conversations on gene therapy, clinical collaboration, and patient advocacy shaping Angelman syndrome research.
Non-viral delivery gene editing takes an important step forward for Angelman syndrome
A FAST-funded study unveils STEP-RNP, a non-viral gene editing platform showing improved motor, cognitive function in AS mice—an early but promising step toward treating Angelman syndrome.
FAST LATAM Brings Families and Research Together in Mexico City
The second FAST LATAM Conference in Mexico City drew 267 in-person and nearly 496 virtual attendees, uniting families across the region around research updates and shared hope.
Using Vocalization Testing to Improve Detection of Treatment Effects in Angelman Syndrome Models
New research adds ultrasonic vocalization testing to Angelman syndrome mouse studies, offering a more sensitive way to detect communication-related changes and evaluate future treatments.
Career Development Awards Expand the Next Wave of Angelman Syndrome Research
FAST and ASGCT are funding three Career Development Awards for early-career scientists, advancing gene editing, siRNA, and delivery approaches to restore UBE3A in Angelman syndrome.
FAST Poland hosts second nationwide conference, “From Diagnosis to Therapy.”
FAST Poland’s second national conference, ‘Between Dreams and Reality,’ drew 134 participants to explore diagnosis, therapy access, and education for the Angelman syndrome community.
Measuring Communication in Angelman Syndrome to Support Better Trials
New research validates ORCA, a caregiver-reported tool for measuring communication in Angelman syndrome, strengthening its use as a meaningful outcome measure in clinical trials.